1. Home
  2. ASG vs FULC Comparison

ASG vs FULC Comparison

Compare ASG & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty All-Star Growth Fund Inc.

ASG

Liberty All-Star Growth Fund Inc.

HOLD

Current Price

$5.01

Market Cap

321.1M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.80

Market Cap

285.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASG
FULC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
321.1M
285.4M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
ASG
FULC
Price
$5.01
$3.80
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
210.6K
1.6M
Earning Date
01-01-0001
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.55
$2.83
52 Week High
$5.69
$15.74

Technical Indicators

Market Signals
Indicator
ASG
FULC
Relative Strength Index (RSI) 34.38 46.72
Support Level $4.98 $3.44
Resistance Level $5.40 $3.92
Average True Range (ATR) 0.05 0.07
MACD -0.02 -0.01
Stochastic Oscillator 9.38 11.85

Price Performance

Historical Comparison
ASG
FULC

About ASG Liberty All-Star Growth Fund Inc.

Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: